title: Response to I. Batinic-Haberle et al.
authors.affiliation: 1 Department of Pharmacology and Personalised Medicine, Cardiovascular Research Institute Maastricht, Faculty of Health, Medicine and Life Sciences, Maastricht University , Maastricht, the Netherlands .
authors.forename: Harald H H W
authors.initials: HH
authors.lastname: Schmidt
authors.affiliation: 2 Victor Chang Cardiac Research Institute , Sydney, Australia .|3 University of New South Wales , Sydney, Australia .
authors.forename: Roland
authors.initials: R
authors.lastname: Stocker
authors.affiliation: 4 Norwegian School of Sport Sciences , Oslo, Norway .
authors.forename: Gøran
authors.initials: G
authors.lastname: Paulsen
authors.affiliation: 5 Brighton & Sussex Medical School , Brighton, United Kingdom .
authors.forename: Pietro
authors.initials: P
authors.lastname: Ghezzi
authors.affiliation: 6 Galera Therapeutics, Inc. , Malvern, Pennsylvania.
authors.forename: Dennis
authors.initials: D
authors.lastname: Riley
authors.affiliation: 7 Labor für Molekulare Kardiologie, Zentrum für Kardiologie, Universitätsmedizin der Johannes Gutenberg-Universität , Mainz, Germany .
authors.forename: Andreas
authors.initials: A
authors.lastname: Daiber
authors.affiliation: 8 Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) , ISCIII, Madrid, Spain .|9 Instituto de Investigaciones Biomédicas "Alberto Sols" UAM-CSIC , Madrid, Spain .|10 Instituto de Investigación Sanitaria La Paz (IdiPaz) , Madrid, Spain .|11 Department of Biochemistry, Faculty of Medicine, Autonomous University of Madrid , Madrid, Spain .
authors.forename: Antonio
authors.initials: A
authors.lastname: Cuadrado